[go: up one dir, main page]

MX2019005151A - Variantes de pertuzumab y su evaluacion. - Google Patents

Variantes de pertuzumab y su evaluacion.

Info

Publication number
MX2019005151A
MX2019005151A MX2019005151A MX2019005151A MX2019005151A MX 2019005151 A MX2019005151 A MX 2019005151A MX 2019005151 A MX2019005151 A MX 2019005151A MX 2019005151 A MX2019005151 A MX 2019005151A MX 2019005151 A MX2019005151 A MX 2019005151A
Authority
MX
Mexico
Prior art keywords
pertuzumab
variants
compositions
molecular weight
evaluation
Prior art date
Application number
MX2019005151A
Other languages
English (en)
Inventor
Lynn A Gennaro
Yung-Hsiang Kao
Yonghua Zhang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50694078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2019005151A publication Critical patent/MX2019005151A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44747—Composition of gel or of carrier mixture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente solicitud describe variantes de pertuzumab. En particular, se revela: una variante de cisteína no apareada que comprende cisteínas Cys23/Cys88 no apareadas en uno o ambos dominios variables livianas de pertuzumab, una variante afucosilada de pertuzumab, una especie de bajo peso molecular (LMWS) de pertuzumab, y una especie de elevado peso molecular (HMWS) de pertuzumab. La solicitud describe además las variantes aisladas, composiciones, composiciones farmacéuticas, y artículos de fabricación que comprenden las variantes, así como también métodos para preparar y caracterizar las variantes y sus composiciones.
MX2019005151A 2013-04-16 2015-10-01 Variantes de pertuzumab y su evaluacion. MX2019005151A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361812603P 2013-04-16 2013-04-16

Publications (1)

Publication Number Publication Date
MX2019005151A true MX2019005151A (es) 2022-06-27

Family

ID=50694078

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013898A MX368259B (es) 2013-04-16 2014-04-15 Variantes de pertuzumab y su evaluacion.
MX2019005151A MX2019005151A (es) 2013-04-16 2015-10-01 Variantes de pertuzumab y su evaluacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015013898A MX368259B (es) 2013-04-16 2014-04-15 Variantes de pertuzumab y su evaluacion.

Country Status (25)

Country Link
US (8) US9815904B2 (es)
EP (3) EP2986643A2 (es)
JP (2) JP2016522176A (es)
KR (2) KR20150143649A (es)
CN (1) CN105121471A (es)
AR (1) AR095863A1 (es)
AU (3) AU2014254086B2 (es)
BR (1) BR112015024926A2 (es)
CA (2) CA2907776C (es)
CL (3) CL2015003049A1 (es)
CR (1) CR20150576A (es)
EA (1) EA201591643A1 (es)
HK (1) HK1211948A1 (es)
IL (2) IL241103B (es)
MA (1) MA38567A1 (es)
MX (2) MX368259B (es)
MY (1) MY173295A (es)
NZ (2) NZ751877A (es)
PE (2) PE20151769A1 (es)
PH (1) PH12015502382A1 (es)
RU (2) RU2019115089A (es)
SG (3) SG10201911353WA (es)
TW (1) TWI554284B (es)
WO (1) WO2014172371A2 (es)
ZA (1) ZA201506594B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
CN104334189A (zh) 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
CA2907776C (en) 2013-04-16 2020-04-14 Genentech, Inc. Pertuzumab variants and evaluation thereof
JP6914336B2 (ja) * 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
EP3868404A1 (en) 2017-01-17 2021-08-25 F. Hoffmann-La Roche AG Subcutaneous her2 antibody formulations
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
CA3059241A1 (en) * 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
WO2019055631A1 (en) 2017-09-13 2019-03-21 Mayo Foundation For Medical Education And Research IDENTIFICATION AND MONITORING OF ACID HYDROLYSIS PRODUCTS OF IMMUNOGLOBULIN HEAVY CHAINS
JP7259778B2 (ja) 2020-01-31 2023-04-18 トヨタ自動車株式会社 車両、及び自動運転システム
EP3892989A1 (en) * 2020-04-07 2021-10-13 Ares Trading S.A. Capillary gel electrophoresis and its use with complex biological molecules
WO2022005499A1 (en) 2020-06-29 2022-01-06 Genentech, Inc. Pertuzumab plus trastuzumab fixed dose combination
EP4190818A4 (en) * 2020-07-28 2024-08-07 Bio-Thera Solutions, Ltd. ANTI-HER2 ANTIBODY AND ITS USE
CN113189184B (zh) * 2021-04-28 2022-09-09 浙江大学 含有半胱氨酸的毛细管凝胶电泳样品缓冲液
JP2024522389A (ja) 2021-04-29 2024-06-19 ハイスリンク セラピューティクス 抗体薬物複合体の調製方法および使用
KR102511384B1 (ko) 2022-04-14 2023-03-16 지용환 곡물의 손상을 줄일 수 있는 도정기
WO2025021118A1 (zh) * 2023-07-25 2025-01-30 海南先声再明医药股份有限公司 配体-药物偶联物及其偶联连接子
GB202313175D0 (en) 2023-08-30 2023-10-11 Univ Oxford Innovation Ltd A bivalent polypeptide scaffold and uses thereof

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE97498T1 (de) 1984-01-30 1993-12-15 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ATE371673T1 (de) 1996-11-27 2007-09-15 Genentech Inc Affinitätsreinigung von polypeptiden an einer protein a-matrix
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CA2324494A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
SI1308455T1 (sl) 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
PT1189634E (pt) 1999-06-25 2007-06-06 Genentech Inc Tratamento de cancro da próstata com anticorpos anti-erbb2.
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US20200048362A1 (en) 2000-03-16 2020-02-13 Immunogen, Inc. Methods of treatment using anti-erbb antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
SI1282443T1 (sl) 2000-05-19 2010-01-29 Genentech Inc Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
JP4731793B2 (ja) 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
DK1358318T3 (da) * 2001-02-07 2007-01-02 Wilex Ag Hybridomcellelinje G250 og dens anvendelse til frembringelse af monoklonale antistoffer
WO2003087131A2 (en) 2002-04-10 2003-10-23 Genentech, Inc Anti-her2 antibody variants
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
JP5069843B2 (ja) 2002-07-15 2012-11-07 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
CA2496060C (en) 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
WO2004048525A2 (en) 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
EP1641827A2 (en) * 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
LT3095793T (lt) 2003-07-28 2020-07-10 Genentech, Inc. Baltymo a išplovimo sumažinimas afininės baltymo a chromatografijos metu
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
EP1753463A2 (en) 2004-06-01 2007-02-21 Genentech, Inc. Antibody drug conjugates and methods
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
KR20150043558A (ko) * 2004-07-22 2015-04-22 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
JP2008523002A (ja) 2004-12-13 2008-07-03 エフ．ホフマン−ラ ロシュ アーゲー 少なくとも１つのドラスタチン１０誘導体を含有する新規な医薬組成物
RU2438705C2 (ru) 2005-01-21 2012-01-10 Дженентек, Инк. Введение фиксированных доз her-антител
CA2596133C (en) 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
WO2006096861A2 (en) 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CA2654584A1 (en) 2006-06-05 2007-12-21 Genentech, Inc. Extending survival of cancer patients with elevated levels of egf or tgf-alpha
US8015939B2 (en) 2006-06-30 2011-09-13 Asml Netherlands B.V. Imprintable medium dispenser
ES2392630T3 (es) 2006-08-21 2012-12-12 F. Hoffmann-La Roche Ag Terapia antitumoral con anticuerpos anti-VEGF
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
AU2008223069B2 (en) 2007-03-02 2012-12-13 F. Hoffmann-La Roche Ag Predicting response to a HER dimerisation inhibitor based on low HER3 expression
TWI464178B (zh) 2007-03-22 2014-12-11 Genentech Inc 細胞凋亡抗-ｉｇｅ抗體
EP1997534A1 (en) 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
US8529901B2 (en) 2007-06-06 2013-09-10 Hoffmann-La Roche, Inc. Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
CN103554215B (zh) 2007-10-30 2016-06-15 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
EP2247310A4 (en) 2008-01-30 2012-06-27 Abbott Lab COMPOSITIONS AND METHODS FOR CRYSTALLIZING ANTIBODY FRAGMENTS
CL2009000545A1 (es) 2008-03-06 2010-10-15 Genentech Inc Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
AU2009225877B2 (en) 2008-03-18 2014-11-20 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
US9235334B2 (en) 2008-05-09 2016-01-12 Genesis Industries, Llc Managing landbases and machine operations performed thereon
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
SG10201507044PA (en) 2009-05-29 2015-10-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR079256A1 (es) 2009-12-04 2012-01-04 Genentech Inc Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1
CN102822201B (zh) * 2009-12-22 2014-09-24 罗切格利卡特公司 抗her3抗体及其用途
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
KR20140009275A (ko) 2010-12-09 2014-01-22 제넨테크, 인크. 파클리탁셀 및 트라스투주맙-mcc-dm1에 의한 her2-양성 암의 치료
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
SG194472A1 (en) * 2011-01-28 2013-12-30 Ca Nat Research Council Engineering of immunoglobulin domains
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
CN104334189A (zh) 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
MX2014014831A (es) 2012-06-08 2015-02-12 Hoffmann La Roche Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
CA2907776C (en) 2013-04-16 2020-04-14 Genentech, Inc. Pertuzumab variants and evaluation thereof
SG11201604956SA (en) 2013-12-17 2016-07-28 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
AU2015249633B2 (en) 2014-04-25 2020-10-15 Genentech, Inc. Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
TW201818940A (zh) 2016-11-04 2018-06-01 美商建南德克公司 Her2陽性乳癌之治療
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
EP3868404A1 (en) 2017-01-17 2021-08-25 F. Hoffmann-La Roche AG Subcutaneous her2 antibody formulations
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
RU2022103533A (ru) 2017-10-20 2022-03-10 Бионтек Рна Фармасьютикалс Гмбх (Biontech Rna Pharmaceuticals Gmbh) Приготовление и хранение липосомальных РНК-составов, подходящих для терапии
WO2022005499A1 (en) 2020-06-29 2022-01-06 Genentech, Inc. Pertuzumab plus trastuzumab fixed dose combination
IL299121A (en) 2020-07-14 2023-02-01 Hoffmann La Roche Tests for fixed dose combinations
MX2023006793A (es) 2020-12-11 2023-06-20 Genentech Inc Tratamientos conjuntos para tratamiento de cancer her2.
EP4493180A1 (en) 2022-03-14 2025-01-22 Genentech Inc. Combination therapies for breast cancer

Also Published As

Publication number Publication date
CL2015003049A1 (es) 2016-06-10
BR112015024926A2 (pt) 2017-10-10
RU2015141520A (ru) 2017-05-22
US20180037660A1 (en) 2018-02-08
US20230047103A1 (en) 2023-02-16
US20250084181A1 (en) 2025-03-13
RU2737727C2 (ru) 2020-12-02
US20140308277A1 (en) 2014-10-16
AR095863A1 (es) 2015-11-18
PH12015502382A1 (en) 2016-02-22
EP3800204A1 (en) 2021-04-07
SG11201508536PA (en) 2015-11-27
EA201591643A1 (ru) 2016-02-29
WO2014172371A2 (en) 2014-10-23
RU2019115089A (ru) 2019-06-11
PE20211214A1 (es) 2021-07-05
WO2014172371A3 (en) 2015-01-08
CL2019002244A1 (es) 2019-11-29
IL275398A (en) 2020-07-30
IL241103A0 (en) 2015-11-30
HK1211948A1 (en) 2016-06-03
AU2014254086A1 (en) 2015-10-08
CA2907776A1 (en) 2014-10-23
CA3071678A1 (en) 2014-10-23
CL2017002445A1 (es) 2018-03-16
CR20150576A (es) 2015-11-20
MX2015013898A (es) 2016-07-08
NZ712012A (en) 2020-04-24
AU2019253804A1 (en) 2019-11-14
US9815904B2 (en) 2017-11-14
EP4483964A3 (en) 2025-04-30
US9969811B2 (en) 2018-05-15
MA38567A1 (fr) 2017-09-29
IL241103B (en) 2020-07-30
TWI554284B (zh) 2016-10-21
CA2907776C (en) 2020-04-14
US20190345258A1 (en) 2019-11-14
US20200157238A1 (en) 2020-05-21
AU2018241141B2 (en) 2019-11-07
KR20200085942A (ko) 2020-07-15
EP4483964A2 (en) 2025-01-01
KR20150143649A (ko) 2015-12-23
JP2020015719A (ja) 2020-01-30
EP4483964A8 (en) 2025-06-18
JP2016522176A (ja) 2016-07-28
TW201442725A (zh) 2014-11-16
US12145998B2 (en) 2024-11-19
ZA201506594B (en) 2018-11-28
MX368259B (es) 2019-09-25
CN105121471A (zh) 2015-12-02
AU2018241141A1 (en) 2018-10-25
US20180037662A1 (en) 2018-02-08
EP2986643A2 (en) 2016-02-24
MY173295A (en) 2020-01-14
NZ751877A (en) 2020-04-24
SG10201706045RA (en) 2017-08-30
AU2014254086B2 (en) 2018-07-05
SG10201911353WA (en) 2020-02-27
US20180037661A1 (en) 2018-02-08
PE20151769A1 (es) 2015-12-11

Similar Documents

Publication Publication Date Title
MX2019005151A (es) Variantes de pertuzumab y su evaluacion.
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
IL244713B (en) Silk potein fragment compositions and articles manufactured therefrom
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
PL3463867T3 (pl) Szyba z sygnalizacją świetlną, pojazd zawierający ją i produkcja
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
UY35661A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que lo s contienen
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
BR112016012146A8 (pt) derivados de aminopiridina como inibidores de quinase da família tam
UY36949A (es) 2,4-dihidroxi-nicotinamidas como agonistas de apj
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
UY35305A (es) Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap)
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
CR20160448A (es) Nuevos derivados de piridina
MX2017003219A (es) Derivados de tetrahidroquinolina como inihbidores de bromodominio.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112015005268A2 (pt) seringa contendo uma composição, em particular farmacêutica, composta por imunoglobulinas, seu método de fabricação e respectivo uso
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
DE102013218545B8 (de) Vorrichtung zur Herstellung von Verpackungseinheiten
BR112013027391A2 (pt) formulação farmacêutica, frasco e kit